Patrick Probst, MD
Urology · Kansas City, MONPI 1619331220
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Johnson & Johnson at 32.2% of the total. 2025 is the largest year on record at $10,428, more than ten times the $347 reported in 2021.
Across 145 payments — averaging $93.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Janssen Global Services, LLC$3K
- Procept Biorobotics Corporation$2K
- Urogen Pharma, Inc.$1K
- Intuitive Surgical$279
- Boston Scientific$277
- plus $3K from 34 others
What the payments were for
- Consulting fees$6,31547%
- Travel & lodging$1,0037%
- Food & beverage$6,22446%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 8 | $4,364 |
| Janssen Global Services, LLC | 11 | $3,242 |
| Procept Biorobotics Corporation | 19 | $1,812 |
| Urogen Pharma, Inc. | 12 | $1,066 |
| Intuitive Surgical | 5 | $279 |
| Boston Scientific | 7 | $277 |
| Histosonics, Inc. | 2 | $263 |
| Teleflex LLC | 4 | $255 |
| Sumitomo Pharma America, Inc. | 6 | $208 |
| Medtronic | 2 | $204 |
| C. R. Bard, Inc. & Subsidiaries | 9 | $168 |
| Koelis Inc. | 2 | $164 |
| AbbVie | 10 | $151 |
| Antares Pharma, Inc. | 7 | $117 |
| Merck | 5 | $105 |
| Janssen Scientific Affairs, LLC | 1 | $80 |
| Blue Earth Diagnostics | 4 | $74 |
| Olympus America Inc. | 4 | $70 |
| Baxter Healthcare | 1 | $63 |
| TELA Bio, Inc. | 1 | $56 |
| Axogen | 2 | $55 |
| BD | 1 | $42 |
| Coloplast | 2 | $41 |
| Calyxo, Inc. | 2 | $40 |
| Immunitybio, Inc. | 2 | $35 |
| 180 Medical, Inc. | 1 | $34 |
| Halozyme Inc | 2 | $33 |
| Telix Pharmaceuticals | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $18 |
| UCB, Inc. | 1 | $17 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,454
- JELMYTO$601
- ZUSDURI$287
- UroLift$205
- Signia$179
- TRINITY$141
- GENERAL ERECTILE DYSFUNCTION$119
- GEMTESA$119
- AQUABEAM SYSTEM$117
How this compares
$13,559 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 25 | $22,162 |
| GemtesaVibegron | 17 | $21,548 |
| Tamsulosin Hcl | 408 | $4,683 |
| Potassium Citrate ErPotassium Citrate | 37 | $2,289 |
| Testosterone | 15 | $2,194 |
| Finasteride | 131 | $1,798 |
| Oxybutynin Chloride ErOxybutynin Chloride | 56 | $1,021 |
| Estradiol | 15 | $813 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $246 |
| Oxybutynin Chloride | 50 | $196 |
| Amitriptyline Hcl | 14 | $123 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $120 |
| Desmopressin Acetate | 11 | $103 |
| Tramadol Hcl | 14 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $20 | $22,16225 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $208 | $21,54817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.
Other urology in Kansas City
- Samuel KuykendallKansas City$141K
- Donald NeffKansas City$27K
- Lukas HockmanKansas City$14K
- Daniel HolmesKansas City$9K
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.